We are live on ! Find out more
BDRX icon

Biodexa Pharmaceuticals
BDRX

3 hedge funds and large institutions have $17K invested in Biodexa Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

2.8% less ownership

Funds ownership: 3.19% → 0.39% (-2.8%)

11% less capital inflows, than outflows

Capital inflows: $20.4K | Capital outflows: $22.9K

25% less funds holding

Funds holding: 4 → 3 (-1)

50% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 2

Holders
3
Holders Change
-1
Holders Change %
-25%
% of All Funds
0.04%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
1
Reduced
1
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
GAMMA Investing
GAMMA Investing
California
+$13.3K
2
SBI Securities
SBI Securities
Japan
+$7.14K

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$21.4K
2
Morgan Stanley
Morgan Stanley
New York
-$924
3
RhumbLine Advisers
RhumbLine Advisers
Massachusetts
-$510
4
Contravisory Investment Management
Contravisory Investment Management
Massachusetts
-$53

BDRX Hedge Fund Activity: Q2 2025 in Review

3 of the 7,628 institutional investors tracked by Wall St. Rank reported a position in Biodexa Pharmaceuticals (BDRX) for Q2 2025, worth a combined $17K — down 40% from $28.1K a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of BDRX and 1 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 1 added.

The largest buyer was GAMMA Investing, adding an estimated $13.3K. The largest seller was UBS Group, cutting an estimated $21.4K.

  • 3 institutional investors held Biodexa Pharmaceuticals (BDRX) as of Q2 2025, down from 4 in Q1 2025.
  • Funds reported $17K of Biodexa Pharmaceuticals stock for Q2 2025, down 40% quarter-over-quarter.
  • 1 fund opened new Biodexa Pharmaceuticals positions in Q2 2025 and 2 closed out, a net change of -1 holder.
  • The largest Biodexa Pharmaceuticals buyer in Q2 2025 was GAMMA Investing, an estimated $13.3K added.
  • The largest Biodexa Pharmaceuticals seller in Q2 2025 was UBS Group, an estimated $21.4K sold.

Based on aggregated 13F filings for Q2 2025.